<DOC>
	<DOCNO>NCT01460030</DOCNO>
	<brief_summary>This intra-individual titration study KRN1493 evaluate safety efficacy KRN1493 treatment hypercalcemia patient parathyroid carcinoma intractable primary hyperparathyroidism ( PHPT ) .</brief_summary>
	<brief_title>An Intra-individual Titration Study KRN1493 Treatment Hypercalcemia Patients With Parathyroid Carcinoma Intractable Primary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Parathyroid Neoplasms</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Patients meet one follow . Patients diagnosis parathyroid carcinoma correct serum calcium &gt; 11.3 mg/dL late screen test . Patients intractable PHPT ( define follow : impossible localize parathyroid tumor initial surgery relapse surgery , impossible perform parathyroidectomy ( PTx ) complication , correct serum calcium &gt; 12.5 mg/dL screen test ) . Patients provide voluntary write informed consent participate study . Patients diagnose malignant tumor except parathyroid carcinoma , nonmelanoma skin cancer , carcinoma situ cervix within 5 year enrollment . Patients receive anticancer chemotherapy except treatment parathyroid carcinoma . Patients diagnose hypercalcemia associate malignant tumor parathyroid carcinoma . Patients hypersensitivity cinacalcet HCl preparation vehicle .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypercalcemia patient parathyroid carcinoma intractable PHPT</keyword>
</DOC>